文献速递肝胆胰外科

肝胆胰恶性肿瘤围手术期辅助治疗临床试验中无复发生存期作为总生存期替代终点的有效性:回顾性研究及荟萃分析

Surrogacy of Recurrence-free Survival for Overall Survival as an Endpoint of Clinical Trials of Perioperative Adjuvant Therapy in Hepatobiliary-pancreatic Cancers: A Retrospective Study and Meta-analysis.
PubMed 文献 · Ann Surg · 2023-08-28

该回顾性研究纳入986例胰腺导管腺癌、1168例胆道癌、1043例肝细胞癌和1071例结直肠癌肝转移患者,评估无复发生存期(RFS)与总生存期(OS)的相关性,并对胰腺导管腺癌和胆道癌的新辅助或辅助治疗随机对照试验进行荟萃分析。结果显示胰腺导管腺癌和胆道癌中RFS与OS强相关,3年RFS可作为替代终点。

要点

  • 胰腺导管腺癌和胆道癌中RFS与OS相关系数分别为0.80和0.75,肝细胞癌和结直肠癌肝转移分别为0.67和0.53。
  • 术后5年生存与各时点复发一致性在胰腺导管腺癌和胆道癌均于3年达到平台(74%和73%)。
  • 荟萃分析中胰腺导管腺癌和胆道癌的RFS风险比与OS风险比相关系数分别为0.88和0.87(P<0.001)。

核心结论

  • 3年RFS可作为胰腺导管腺癌和胆道癌新辅助或辅助治疗临床试验中OS的可靠替代终点。

研究设计与样本

  • 回顾性分析2002年9月至2022年6月行根治性切除的肝胆胰疾病患者,包括986例胰腺导管腺癌、1168例胆道癌、1043例肝细胞癌和1071例结直肠癌肝转移。
  • 对胰腺导管腺癌和胆道癌的新辅助或辅助治疗随机对照试验进行荟萃分析以验证替代性。

主要发现

  • RFS与OS的相关系数在肝细胞癌为0.67、结直肠癌肝转移为0.53,在胰腺导管腺癌为0.80、胆道癌为0.75。
  • landmark分析中,术后5年生存或死亡与各时点(1、2、3、4年)复发与否的一致性在胰腺导管腺癌分别为50%、70%、74%、77%,在胆道癌分别为54%、67%、73%、78%,均升高并于3年达到平台。
  • 荟萃分析中,胰腺导管腺癌的RFS风险比与OS风险比相关系数为0.88(P<0.001),胆道癌为0.87(P<0.001)。

关键数值与推荐

  • 胰腺导管腺癌中RFS与OS相关系数为0.80,胆道癌为0.75。
  • 胰腺导管腺癌5年生存与3年复发一致性为74%,胆道癌为73%。
  • 荟萃分析中胰腺导管腺癌RFS风险比与OS风险比相关系数0.88(P<0.001),胆道癌0.87(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the correlation between recurrence-free survival (RFS) and overall survival (OS) in the hepatobiliary-pancreatic (HBP) surgical setting to validate RFS as a surrogate endpoint. BACKGROUND: Reliable surrogate endpoints for OS are still limited in the field of HBP surgery. METHODS: We analyzed patients who underwent curative resection for HBP disease [986 patients with pancreatic ductal adenocarcinoma (PDAC), 1168 with biliary tract cancer (BTC), 1043 with hepatocellular carcinoma, and 1071 with colorectal liver metastasis] from September 2002 to June 2022. We also conducted meta-analyses of randomized controlled trials of neoadjuvant or adjuvant therapy to validate the surrogacy in PDAC and BTC. RESULTS: Correlation coefficients between RFS and OS were low for hepatocellular carcinoma ( p = 0.67) and colorectal liver metastasis ( p = 0.53) but strong for PDAC ( p = 0.80) and BTC ( p = 0.75). In a landmark analysis, the concordance rates between survival or death at 5 years postoperatively and the presence or absence of recurrence at each time point (1, 2, 3, and 4 years) were 50%, 70%, 74%, and 77% for PDAC and 54%, 67%, 73%, and 78% for BTC, respectively, both increasing and reaching a plateau at 3 years. In a meta-analysis, the correlation coefficients for the RFS hazard ratio and OS hazard ratio in PDAC and BTC were p = 0.88 ( P < 0.001) and p = 0.87 ( P < 0.001), respectively. CONCLUSIONS: Three-year RFS can be a reliable surrogate endpoint for OS in clinical trials of neoadjuvant or adjuvant therapy for PDAC and BTC.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Imamura T, Ohgi K, Mori K, et al. Surrogacy of Recurrence-free Survival for Overall Survival as an Endpoint of Clinical Trials of Perioperative Adjuvant Therapy in Hepatobiliary-pancreatic Cancers: A Retrospective Study and Meta-analysis. Ann Surg. 2023. PMID: 37638472. doi:10.1097/SLA.0000000000006084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。